Estimation of efficiency and safety silodosin in treatment of the symptom bottom uric ways and nokturia at patients from good-quality hiperplazie prostate

Authors

  • V.P. Stus SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • N.N. Moiseenko SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • Y.Y. Cepelev SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • S.V. Shomchenko SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • A.A. Mogeyko SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • N.V. Agafonov SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • N.V. Krasnov SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • V.V. Kostura SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • E.G. Olkchowskaya SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • E.L. Fidelev SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • K.A. Hramov SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • I.M. Rusinko SI “Institute of Urology NAMS of Ukraine”, Ukraine
  • A.A. Kravec SI “Institute of Urology NAMS of Ukraine”, Ukraine

DOI:

https://doi.org/10.26641/2307-5279.21.1.2017.150131

Keywords:

good-quality hiperplazie prostate, symptoms of the bottom uric ways, silodozint, efficiency of application

Abstract

Symptoms of the bottom uric ways against good-quality hiperplazie prostate represent a frequent problem at men of the senior age group and meet in 43 % of cases after 70 years. For elimination of the given symptoms used treatment by a preparation of Urorek (silodozine) in doses of 4 mg and 8 mg a day within 1–2 months. In research participated 236 patient with good-quality hiperplazie prostate. Age of patients from 52 to 88 years. Efficiency of action of a preparation on disease symptoms estimated on scale IPSS. Simultaneously carried out monitoring of indicators of arterial pressure at all patients. It is established that in 8 weeks of treatment decrease IPSS at patients who received a preparation in a dose of 8 mg with 18,9±9 points to 12,3±6 (31%) a point is marked. At patients who accepted a preparation in a dose of 4 mg a day, decrease in points has made from 16,0±8 to 11,3±5 (29 %). The volume of residual urine has decreased in 1 group for 68 %, 2 – group for 51%. The By-effect in a kind retrograde eyaculation, directly correlated with decrease in symptoms of the bottom uric ways. The preparation did not render essential influence on a condition of arterial pressure at patients at all stages of treatment. The conducted research has shown high enough efficiency of application of a preparation of Urorek (silodosin) for treatment of frustration urination at patients with good-quality hiperplazie prostate.

References

Change of expression levels of a1-adrenoceptor subtypes by administration of alpha 1d-adrenoceptor-subtypeselective antagonist naftopidil in benign prostate hyperplasia patients / Kojima Y., Sasaki S., Shinoura H. et al. // Prostate. – 2007. – V. 67. – P. 1285–1292.

Djavan B., Marberger M. Meta-analysis on the efficacy and tolerability of a1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction // Eur. Urol. – 1999. – V. 36. – P. 1–3.

Identification, quantification, and localization of mRNA for three distinct alpha A1 adrenergic receptor subtypes in human prostate / Price D.T., Schwinn D.A., Lomasney J.W. et al. // J. Urol. – 1993. – V. 150. – P. 546–551.

Matsukawa Y. Long-term efficacy of silodosin on the lower urinary tract function in patients with benign prostatic hyperplasia according to prostate size: prospective investigation using pressure-flow study / Matsukawa Y., Hattori R., Yanamoto T. et al. // Eur. Urol. Suppl. – 2011. – V. 10(2). – P. 121.

Prospective Randomized Placebo-controlled Study to Assess the Safety and Efficacy of Silodosin in the Management of Acute Urinary Retention. – 2013.

Michel M.C., Casi M., Anonellini A. Silodosin consistently improves nocturia in men with LUTS suggestive of BPH. Analysis of three phase III placebo-controlled studies // Eur. Urol. – 2011. – V. 10(2). – P. 121–122.

Montorsi F. Profi le of silodosin // Eur. Urol. Suppl. – 2010. – V. 9. – P. 491–495.

Nickel J.C., O’Leary M.P., Lepor H. et al. Silodosin for men with chronic prostatitis chronic pelvic pain syndrome: results of a phase multicenter, double-blind, placebo controlled study // J. Urol. – 2011. – V. 186. – P. 125–131.

Russo A., Hedlund P., Montorsi F. Silodosin from bench to bedside: selectivity, safety, and sustained efficacy // Eur. Urol. Suppl. – 2011. – V. 10. – P. 445–450.

Santosh Kumar, D. Prasad, Tiwari, Shrawan K. Singh, Yoshida M., Kudoh J., Homma Y. et al. Safety and effi cacy of silodosin for the treatment of benign prostatic hyperplasia // Clin. Interv. Aging. – 2011. – V. 6. – P. 161–172.

Yu H.J., Lin A.T., Yang S.S. et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) // Br. J. Urol. Int. – 2011. – V. 108(11). – P. 1843–1848.

Downloads

Published

2018-12-07

Issue

Vol. 21 No. 1 (2017)

Section

Urology

License

Стаття повинна мати візу керівника та офіційне направлення від установи, з якої виходить стаття (з круглою печаткою), і вказівкою, чи є стаття дисертаційною, а також у довільній формі на окремому аркуші - відомості про авторів (прізвище, ім’я, по батькові, посада, вчений ступінь, місце роботи, адреса, контактні телефони, E-mail).

Стаття повина бути підписана всіма авторами, які укладають з редакцією договір пропередачу авторських прав (заповнюється на кожного автора окремо з оригінальним підписом). За таких умов редакція має право на її публікацію та розміщення на сайті видавництва.